Insulin use and increased risk of mortality in type 2 diabetes: a cohort study

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2010-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1463-1326.2009.01125.xPMID 19788429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucose control and vascular complications in veterans with type 2 diabetes.

  2009cited by this paper
• Insulin‐induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study

  2009cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes The Action to Control Cardiovascular Risk in Diabetes Study Group

  2008cited by this paper
• Relationship of Glycemic Control, Exogenous Insulin, and C-Peptide Levels to Ischemic Heart Disease Mortality Over a 16-Year Period in People With Older-Onset Diabetes

  2008cited by this paper
• Cardiovascular events and insulin therapy: a retrospective cohort analysis.

  2008cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point?

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Association between serious ischemic cardiac outcomes and medications used to treat diabetes

  2008cited by this paper
• Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies.

  2007cited by this paper
• Health Services Databases in Saskatchewan

  2007cited by this paper
• Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control.

  2006cited by this paper
• Observational studies of drugs and mortality.

  2005cited by this paper
• Insulin treatment and cardiovascular disease; friend or foe? A point of view

  2005cited by this paper
• High cumulative insulin exposure: a risk factor of atherosclerosis in type 1 diabetes?

  2005cited by this paper
• The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort.

  2004cited by this paper
• The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort.

  2004cited by this paper
• Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

  2002cited by this paper
• Nontraditional Risk Factors for Coronary Heart Disease Incidence among Persons with Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study

  2000cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000influential reference
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Insulin and risk of cardiovascular disease: a meta-analysis.

  1998cited by this paper
• Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes.

  1997cited by this paper
• The insulin-sparing effect of metformin in insulin-treated diabetic patients.

  1995cited by this paper
• A chronic disease score from automated pharmacy data.

  1992cited by this paper
• The insulin sparing effect of metformin in insulin-treated diabetic patients.

  1991cited by this paper
• Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics.

  1987cited by this paper

• Type 2 Diabetes Mellitus Versus Adverse In-Hospital Outcomes After Partial or Radical Nephrectomy.

  2026cites this paper
• Immune Dysregulation Connecting Type 2 Diabetes and Cardiovascular Complications

  2025cites this paper
• Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on insulin: a network meta-analysis

  2025cites this paper
• The complications of long time treatment of insulin therapy in type-2 diabetes patients: A Review

  2024influential citation
• Use of electronic health records for the management of diabetes and its risk factors in the Principality of Asturias from 2014 to 2018.

  2024cites this paper
• DAPAGLIFLOZIN: A NEW HOPE FOR THE THERAPEUTIC TREATMENT OF TYPE 2 DIABETES MELLITUS

  2024cites this paper
• Age‐ and gender‐adjusted estimated glomerular filtration rate definition reveals hyperfiltration as a risk factor for renal function deterioration in type 2 diabetes

  2024cites this paper
• Comparing the Efficacy and Long-Term Outcomes of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Metformin, and Insulin in the Management of Type 2 Diabetes Mellitus

  2024cites this paper
• Comparison of GLP-1 Receptor Agonists and Other Glucose-Lowering Agents on Cardiovascular Outcomes in Individuals with Type 2 Diabetes and Obesity: A Spanish Real-World Population-Based Study.

  2023cites this paper
• Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease.

  2023cites this paper
• Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential.

  2023cites this paper
• Effect of dipeptidyl peptidase‐4 inhibitor on the progression of coronary artery disease evaluated by computed tomography in patients receiving insulin therapy for type 2 diabetes mellitus

  2023cites this paper
• Preadmission Insulin-Treated Type 2 Diabetes Mellitus Patients Had Increased Mortality in Intensive Care Units

  2022influential citation
• Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia

  2022cites this paper
• Hyperinsulinemia and plasma glucose level independently associated with all-cause and cardiovascular mortality in Chinese people without diabetes-A post-hoc analysis of the 30-year follow-up of Da Qing diabetes and IGT study.

  2022cites this paper
• Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease

  2022cites this paper
• The Current Schemes of Insulin Therapy: Pro and Contra.

  2021cites this paper
• Endocrinología, Diabetes y Nutrición: repaso del año 2021

  2021cites this paper
• The Effects of Glucose Lowering Agents on the Secondary Prevention of Coronary Artery Disease in Patients with Type 2 Diabetes

  2021cites this paper
• Insulin Treatment Is Associated With Increased Mortality in Critically Ill Patients With Type 2 Diabetes in the Intensive Care Unit

  2021cites this paper
• The effects of insulin therapy on mortality in diabetic patients undergoing percutaneous coronary intervention

  2021cites this paper
• Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial

  2021cites this paper
• Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes

  2021cites this paper
• Impacts of early insulin treatment vs glimepiride in diabetic patients with background metformin therapy

  2021cites this paper
• Insulin Therapy Is Associated With an Increased Risk of Carotid Plaque in Type 2 Diabetes: A Real-World Study

  2021cites this paper
• Efficacy and Cardiovascular Safety of Antidiabetic Medications

  2021cites this paper
• Effects of the low carbohydrate, high fat diet on glycemic control and body weight in patients with type 2 diabetes: experience from a community-based cohort

  2020cites this paper
• Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes

  2020cites this paper
• Reducing the Burden of Mortality in Older People With Diabetes: A Review of Current Research

  2020cites this paper
• The effects of dual-therapy intensification THE EFFECTS OF DUAL THERAPY INTENSIFICATION WITH INSULIN OR DPP-4 INHIBITOR ON CARDIOVASCULAR EVENTS AND ALL-CAUSE MORTALITY IN PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY

  2020cites this paper
• Heart failure in diabetes mellitus: an updated review.

  2020cites this paper
• Alternatives to Insulin for the Regulation of Blood Sugar Levels in Type 2 Diabetes

  2020cites this paper
• Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus

  2020cites this paper
• Insulin: too much of a good thing is bad

  2020cites this paper
• Independent effects of 15 commonly prescribed drugs on all-cause mortality among US elderly patients with type 2 diabetes mellitus

  2020cites this paper
• Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial

  2020cites this paper
• Effects of basal insulin on lipid profile compared to other classes of anti-hyperglycaemic agents in type 2 diabetic patients.

  2020cites this paper
• Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?

  2020cites this paper
• Diabetes and the Cardiovascular System

  2020cites this paper
• Insulin resistance: Unsolved issues of harm and use

  2020cites this paper
• Diabetes pay-for-performance program can reduce all-cause mortality in patients with newly diagnosed type 2 diabetes mellitus

  2020cites this paper
• The Association Between Insulin Initiation and Adverse Outcomes After Hospital Discharge in Older Adults: a Population-Based Cohort Study

  2019cites this paper
• Competing risks modeling of cumulative effects of time-varying drug exposures

  2019cites this paper
• Motivating people to sustain healthy lifestyles using persuasive technology: A pilot study of Korean Americans with prediabetes and type 2 diabetes.

  2019cites this paper
• Relationship between HbA1c and all-cause mortality in older patients with insulin-treated type 2 diabetes: results of a large UK Cohort Study

  2019cites this paper
• The Association Between Insulin Initiation and Adverse Outcomes After Hospital Discharge in Older Adults : a Population-Based Cohort Study

  2019cites this paper
• The association of intravenous insulin and glucose infusion with intensive care unit and hospital mortality: a retrospective study

  2019cites this paper
• Carbohydrate Restriction in Type 1 Diabetes: A Realistic Therapy for Improved Glycaemic Control and Athletic Performance?

  2019cites this paper
• Evaluation of weight change and hypoglycaemia as mediators in the association between insulin use and death

  2019cites this paper
• Metformin, statins and the risk and prognosis of endometrial cancer in women with type 2 diabetes

  2019cites this paper
• Administration of metformin in type 2 diabetes mellitus patients with chronic kidney disease; facts and myths

  2019cites this paper
• Cardiovascular Risk Factors in Diabetic Patients according Duration of Diabetes Mellitus: The Sixth Korea National Health and Nutrition Examination Survey

  2018cites this paper
• MORTALITY IN PATIENTS WITH TYPE 2 DIABETES : A RETROSPECTIVE COHORT STUDY

  2018cites this paper
• Excess insulin and hypoxia, linkages to obesity and type 2 diabetes

  2018cites this paper
• Pulse pressure and diabetes treatments

  2018cites this paper
• The changes of inflammatory markers and irisine level in the first year of insulin therapy in type 2 diabetes patients

  2018cites this paper
• Self-management levels of diet and metabolic risk factors according to disease duration in patients with type 2 diabetes

  2018cites this paper
• Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect

  2018cites this paper
• The impact of cardiovascular outcome trials on the choice of insulins in the management of type 2 diabetes mellitus: An expert review

  2018cites this paper
• Atherosclerosis is a vascular stem cell disease caused by insulin.

  2018cites this paper
• The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data

  2018cites this paper
• The association study of high-sensitivity C-reactive protein, pentraxin 3, nitrotyrosine, and insulin dose in patients with insulin-treated type 2 diabetes mellitus

  2018cites this paper
• Risk stratification according to insulin type

  2018cites this paper
• Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells

  2018cites this paper
• Hospital Readmission and Social Risk Factors Identified from Physician Notes

  2018cites this paper
• The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients

  2018cites this paper
• Insulin Therapy and Stroke Risk in Patients With Diabetes and Atrial Fibrillation: Guilty by Association?

  2017cites this paper
• The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study

  2017cites this paper
• Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study.

  2017cites this paper
• Mortality in older people with diabetes: A review of current research

  2017cites this paper
• Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan

  2017cites this paper
• Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes.

  2017cites this paper
• Insulin Therapy Increases Cardiovascular Risk: Time for a Sea of Change in Type 2 Diabetes Treatment

  2017cites this paper
• Pathophysiological Construct of Diabetes and its Complications

  2017cites this paper
• Are all people with diabetes and cardiovascular risk factors or microvascular complications at very high risk? Findings from the Risk and Prevention Study

  2017cites this paper
• Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection

  2017cites this paper
• Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.

  2017cites this paper
• Impact of type 2 diabetes mellitus on recurrent myocardial infarction in China

  2016cites this paper
• Dose d’insuline et mortalité cardiovasculaire : nouvelles données de l’étude ACCORD

  2016cites this paper
• Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study.

  2016cites this paper
• Insulin Initiation in Type 2 Diabetes – Why, When and How?

  2016cites this paper
• Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials

  2016cites this paper
• Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study

  2016cites this paper
• Type 2 diabetes therapeutic strategies: why don't we see the «ELEPHANT» in the room?

  2016cites this paper
• Metformin in advanced chronic kidney disease: are current guidelines overly restrictive?

  2016cites this paper
• Effects on All-cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-analysis of Randomized Controlled Trials.

  2016cites this paper
• Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications

  2016cites this paper
• All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine

  2016cites this paper
• Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes

  2015cites this paper
• Insulin therapy in insulin resistance: could it be part of a lethal pathway?

  2015cites this paper
• Glucose‐lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all‐cause mortality, cardiovascular events and cancer

  2015cites this paper
• Insulin Dose and Cardiovascular Mortality in the ACCORD Trial

  2015cites this paper
• Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.

  2015cites this paper
• Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review

  2015cites this paper
• Addressing Limitations in Observational Studies of the Association Between Glucose-Lowering Medications and All-Cause Mortality: A Review

  2015cites this paper
• Cardiovascular risk profiles in Type 2 diabetes and the impact of geographical setting

  2015cites this paper
• High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular events.

  2015cites this paper
• The roles of genetics and glycaemic control in the development of LVH and Heart Failure in Type 2 Diabetes

  2015cites this paper
• A study of the descriptive epidemiology and clinical effectiveness of treatment for type 2 diabetes using routine general practice data

  2015cites this paper
• New forms of insulin and insulin therapies for the treatment of type 2 diabetes.

  2015cites this paper